More Trump Idiocy: No Benefit from Hydroxychloroquine for COVID-19

8
1051

No Benefit from Hydroxychloroquine for COVID-19

by

In March Trump tweeted: “HYDROXYCHLOROQUINE & AZITHROMYCIN, taken together, have a real chance to be one of the biggest game changers in the history of medicine. The FDA has moved mountains – Thank You!” He has continued to support this untested drug since, turning what should have been a minor footnote in the COVID-19 pandemic into a political controversy.

As evidence of putting politics above science, Dr. Rick Bright claims he was removed from his post simply for questioning the promotion of hydroxychloroquine:

Dr. Rick Bright was abruptly dismissed this week as the director of the Department of Health and Human Services’ Biomedical Advanced Research and Development Authority, or BARDA, and removed as the deputy assistant secretary for preparedness and response. He was given a narrower job at the National Institutes of Health.

In a scorching statement, Dr. Bright assailed the leadership at the health department, saying he was pressured to direct money toward hydroxychloroquine, one of several “potentially dangerous drugs promoted by those with political connections” and repeatedly described by the president as a potential “game changer” in the fight against the virus.

The Plandemic conspiracy theorists promoted hydroxychloroquine as a cure for the pandemic, suggesting the government (yes, the same one headed by Trump) was withholding it to make money off an eventual vaccine.

The right wing media has championed the drug, seeing it, apparently, as a way of supporting Trump, and characterizing any criticism of the drug as a means of undermining the president. Most enthusiastic among them is probably Laura Ingraham. In a sly anti-science statement she said: “I love everybody, love the medical profession. But they want a double-blind controlled study on whether the sky is blue.”

The implication here is that the effectiveness of hydroxychloroquine in treating COVID-19 is obvious, based on anecdotal evidence and selected preliminary reports, and so why are we wasting our time with further more rigorous study?

Meanwhile, the majority of the medical profession was appropriately cautious.  David Gorski wrote about it on March 23 concluding:

The bottom line is that more data are desperately needed. Sadly, the French study doesn’t provide us with the data needed and has muddied the waters more than clarified whether using hydroxychloroquine to treat COVID-19 is an effective intervention.

I first mentioned in on April 8th, concluding:

The probability that hydroxychloroquine will turn out to be an effective treatment for COVID-19 is not zero as there is some encouraging pre-clinical data. But the probability, based just on pre-clinical data, is extremely low. Most treatments that look encouraging don’t pan out, for a variety of reasons. It is perhaps more likely that this drug will cause more deaths and harm from side effects and other unintended consequences (like depriving people who actually need the drug) than it will help with the pandemic. At this point all we can say is that rigorous clinical trials are needed. But this requires patience, and that is in short supply during a crisis.

Fauci and other experts basically took the position that this drug should be studied, and should not be taken outside a clinical trial, or at least a controlled medical setting. So who was right, the experts or the political pundits? I think you know the answer.

In the last week four large studies of hydroxychloriquine have been published in prestigious journals, two in the BMJ, one in JAMA, and one in the New England Journal of Medicine. All four studies were negative – they showed no benefit from hydroxychloroquine in COVID-19. But let’s give a quick summary of each study.

One of the studies, a study from China published in the BMJ, was a controlled trial (the other three are observational). This included 150 mild to moderate patients, 75 randomized to getting hydroxychloroquine and 75 usual care. The main outcome was negative seroconversion (blood test for the coronavirus becoming negative after being positive). They also followed clinical outcome and adverse events. They found:

Administration of hydroxychloroquine did not result in a significantly higher probability of negative conversion than standard of care alone in patients admitted to hospital with mainly persistent mild to moderate covid-19. Adverse events were higher in hydroxychloroquine recipients than in non-recipients.

The second BMJ article was from France, and involved 181 patients with COVID-19 requiring oxygen therapy. Here are the numbers:

In the weighted analyses, the survival rate without transfer to the intensive care unit at day 21 was 76% in the treatment group and 75% in the control group (weighted hazard ratio 0.9, 95% confidence interval 0.4 to 2.1). Overall survival at day 21 was 89% in the treatment group and 91% in the control group (1.2, 0.4 to 3.3). Survival without acute respiratory distress syndrome at day 21 was 69% in the treatment group compared with 74% in the control group (1.3, 0.7 to 2.6). At day 21, 82% of patients in the treatment group had been weaned from oxygen compared with 76% in the control group (weighted risk ratio 1.1, 95% confidence interval 0.9 to 1.3). Eight patients in the treatment group (10%) experienced electrocardiographic modifications that required discontinuation of treatment.

As you can see, there is no effect at all here. There is no even a trend toward improvement with the drug, so you cannot argue that the study was just underpowered. Of note, 10% of the treated patients had to stop the drug because of EKG changes. Hydroxychloroquine is known to cause dangerous rhythm changes in the heart. If these patients were not being carefully monitored, they may have suffered cardiac death as a result of treatment.

The JAMA and NEJM studies were both larger studies, involving 1438 and 1446 patients respectively. The JAMA study was a multicenter study in New York State, and the NEJM study was performed in a major hospital in New York City. And their conclusions, JAMA first:

Among patients hospitalized in metropolitan New York with COVID-19, treatment with hydroxychloroquine, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality.

And NEJM

In this observational study involving patients with Covid-19 who had been admitted to the hospital, hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death.

And again, there wasn’t even a beneficial trend. If anything, most of the data was trending negative for hydroxychloroquine, although not statistical significant. As each of the four article pointed out, this data is not definitive because they are not large randomized double-blind controlled trials (you know, the kind that Ingraham says is not necessary). But what does that mean? Do we have to do such trials? I don’t think so, even though they are happening.

The current level of evidence, multiple large trials that are observational but rigorous in different settings with different researchers, all finding no benefit, and if anything a negative or neutral trend, is pretty damning. This is the level of evidence that would be used to determine if the investment and risk to patients of doing controlled trials is worth it, and the answer would likely be no.

The question we have to ask is this – if there were any benefit from hydroxychloroquine in COVID-19 would we be seeing some evidence of that benefit in this data. The answer is – almost certainly yes. Any clinically significant effect should be apparent in the existing data. Of course we cannot rule out a tiny effect – the smaller the effect, the larger the trials needed to see it, and we can never rule out a zero effect. But we can answer the question for an effect big enough to be clinically significant, and that answer is very likely to be – no effect from hydroxychloroquine. The probability that more rigorous or larger studies will find a significant effect missed by these trials is vanishingly small.

In addition, scientists have been publishing and updating systematic reviews and metaanalysis of all hydroxychloroquine COVID-19 studies in real time to provide updated information. The most recent one using data published up to May 14th (so it should include these four studies) concluded:

This systematic review and meta-analysis not only showed no clinical benefits regarding HCQ treatment with/without azithromycin for COVID-19 patients, but according to multiple sensitivity analysis, the higher mortality rates were observed for both HCQ and HCQ+AZM regimen groups, especially in the latter.

Some risk, no benefit. They include the usual caveats that most of the data is observational. But again, any significant benefit should be showing itself in this data.

Experts were cautious about hydroxychloroquine for a reason.

About VT Editors
VT Editors is a General Posting account managed by Jim W. Dean and Gordon Duff. All content herein is owned and copyrighted by Jim W. Dean and Gordon Duff
ATTENTION READERS
Due to the nature of independent content, VT cannot guarantee content validity.
We ask you to Read Our Content Policy so a clear comprehension of VT's independent non-censored media is understood and given its proper place in the world of news, opinion and media.

All content is owned by author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners or technicians. Some content may be satirical in nature. All images within are full responsibility of author and NOT VT.

About VT - Read Full Policy Notice - Comment Policy

8 COMMENTS

  1. this fuker Trump as He’s going Around NO Mask, NO Gloves So then this Fuker better At Least LIE the part …… BUT One Problem , IF This Bonehead Think that a Few Quinine Will get him by , then WE ALL Should better Start Waiting for OUR New Leader Coz soon this fuker’s gonna be Dead thanks to the virus , bojo survived but Trump’s EGO is TOO TOO BIG ………..

  2. All this talk about Hydroxychloroquine working or not. From what I’ve seen, reports of it not working have always neglected the adding of adding Zinc, and therefore support the narrative of it’s effectiveness. On the other hand, I’ve heard nothing but positive reviews when both are combined. While discussing it’s effectiveness, why omit this combination?

    • Right on target Neil. They deliberately fail to mention Zn because they want the treatment to fail even though Dr. Zelenko successfully treated nearly 700 patients with the virus using HCQ, Zn and an antibiotic. My understanding is that the HCQ acts to transport the Zn into the cells where the Zn stops the virus from replicating. End of virus.

  3. Hydroxychloroquine with zinc, from all the articles I read, is a better choice than a VACCINE. Are the VT editors promoting a vaccine and if there is one, will you all get an injection? and to Hoops Kevinski, what kind of a kickback can you get from a medication that costs about 50 cents a pill, has been around for at least 40 years and is out of patent?

  4. There are just as many reports, hydroxychloroquine / with zinc, does work, in particular by GP doctors all over and less known, because who wants to know that, in Iceland, where the IC’s are empty because Iceland’s patients are treated at home with hydroxychloroquine / with zinc and appear to be doing quite well.

  5. “Always Be Closing”!

    Famous salesman line by… Alec Baldwin (Now the spoof Trump… as if the real one wasn’t farcical enough.)

    The #TrumpU Salesman really… pushing hydroxy. Clearly getting kickbacks:

    “Hydroxychloroquine: What The Hell Do You Have To Lose?”

    “Here’s my evidence: I get a lot of positive comments about it”.

    “I’m Taking It Myself”…